JP2713715B2 - 新規骨誘導組成物 - Google Patents
新規骨誘導組成物Info
- Publication number
- JP2713715B2 JP2713715B2 JP62504617A JP50461787A JP2713715B2 JP 2713715 B2 JP2713715 B2 JP 2713715B2 JP 62504617 A JP62504617 A JP 62504617A JP 50461787 A JP50461787 A JP 50461787A JP 2713715 B2 JP2713715 B2 JP 2713715B2
- Authority
- JP
- Japan
- Prior art keywords
- starts
- amino acid
- acid sequence
- amino acids
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002138 osteoinductive effect Effects 0.000 title description 35
- 239000000203 mixture Substances 0.000 title description 26
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 36
- 210000004027 cell Anatomy 0.000 claims description 53
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 45
- 102100026632 Mimecan Human genes 0.000 claims description 40
- 101800002327 Osteoinductive factor Proteins 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 230000011164 ossification Effects 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 24
- 238000003556 assay Methods 0.000 claims description 15
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 230000022159 cartilage development Effects 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 4
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 42
- 241000283690 Bos taurus Species 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000007547 defect Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000003239 periodontal effect Effects 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 98
- 102000004169 proteins and genes Human genes 0.000 description 73
- 235000018102 proteins Nutrition 0.000 description 69
- 239000000523 sample Substances 0.000 description 55
- 239000012634 fragment Substances 0.000 description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 31
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 28
- 239000003102 growth factor Substances 0.000 description 28
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 26
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 26
- 230000008468 bone growth Effects 0.000 description 24
- 238000009396 hybridization Methods 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000011159 matrix material Substances 0.000 description 16
- 108091034117 Oligonucleotide Proteins 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 14
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 239000004202 carbamide Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 13
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 12
- 102000004142 Trypsin Human genes 0.000 description 11
- 108090000631 Trypsin Proteins 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000012588 trypsin Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 239000000020 Nitrocellulose Substances 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 229920001220 nitrocellulos Polymers 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 210000000845 cartilage Anatomy 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 241001515965 unidentified phage Species 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 101001121082 Homo sapiens Mimecan Proteins 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010017076 Fracture Diseases 0.000 description 5
- 101000695352 Homo sapiens Bone morphogenetic protein 1 Proteins 0.000 description 5
- 102000003839 Human Proteins Human genes 0.000 description 5
- 108090000144 Human Proteins Proteins 0.000 description 5
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 108010022394 Threonine synthase Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 102000004419 dihydrofolate reductase Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
- 102000055616 human OGN Human genes 0.000 description 5
- 238000001155 isoelectric focusing Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229960000789 guanidine hydrochloride Drugs 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 210000000078 claw Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010061363 Skeletal injury Diseases 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000045875 human BMP1 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 210000005009 osteogenic cell Anatomy 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101150061927 BMP2 gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000975394 Evechinus chloroticus Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 101100218949 Rattus norvegicus Bmp3 gene Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- WZRZTHMJPHPAMU-UHFFFAOYSA-L disodium;(3e)-3-[(4-amino-3-sulfonatophenyl)-(4-amino-3-sulfophenyl)methylidene]-6-imino-5-methylcyclohexa-1,4-diene-1-sulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(=N)C(C)=CC1=C(C=1C=C(C(N)=CC=1)S([O-])(=O)=O)C1=CC=C(N)C(S(O)(=O)=O)=C1 WZRZTHMJPHPAMU-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000045896 human BMP2 Human genes 0.000 description 1
- 102000045888 human BMP3 Human genes 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108091005979 iodinated proteins Proteins 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003458 metachromatic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- -1 pore size Chemical compound 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Steroid Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88077686A | 1986-07-01 | 1986-07-01 | |
| US880,776 | 1986-07-01 | ||
| US94333286A | 1986-12-17 | 1986-12-17 | |
| US943,332 | 1986-12-17 | ||
| US2828587A | 1987-03-20 | 1987-03-20 | |
| US28,285 | 1987-03-20 | ||
| US31,346 | 1987-03-26 | ||
| US07/031,346 US4877864A (en) | 1987-03-26 | 1987-03-26 | Osteoinductive factors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5130389A Division JP2729222B2 (ja) | 1986-07-01 | 1993-06-01 | 新規骨誘導組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02500241A JPH02500241A (ja) | 1990-02-01 |
| JP2713715B2 true JP2713715B2 (ja) | 1998-02-16 |
Family
ID=27487661
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62504617A Expired - Lifetime JP2713715B2 (ja) | 1986-07-01 | 1987-06-30 | 新規骨誘導組成物 |
| JP5130389A Expired - Lifetime JP2729222B2 (ja) | 1986-07-01 | 1993-06-01 | 新規骨誘導組成物 |
| JP09171615A Expired - Lifetime JP3093682B2 (ja) | 1986-07-01 | 1997-06-27 | 新規骨誘導組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5130389A Expired - Lifetime JP2729222B2 (ja) | 1986-07-01 | 1993-06-01 | 新規骨誘導組成物 |
| JP09171615A Expired - Lifetime JP3093682B2 (ja) | 1986-07-01 | 1997-06-27 | 新規骨誘導組成物 |
Country Status (18)
| Country | Link |
|---|---|
| EP (3) | EP0688869B1 (enExample) |
| JP (3) | JP2713715B2 (enExample) |
| AT (3) | ATE141928T1 (enExample) |
| AU (1) | AU613314B2 (enExample) |
| CA (1) | CA1341212C (enExample) |
| DE (4) | DE3752393D1 (enExample) |
| DK (2) | DK172275B1 (enExample) |
| ES (1) | ES2007625A6 (enExample) |
| GR (1) | GR871028B (enExample) |
| IE (1) | IE75881B1 (enExample) |
| IL (1) | IL83003A (enExample) |
| LU (1) | LU91005I2 (enExample) |
| MX (1) | MX170919B (enExample) |
| MY (1) | MY102505A (enExample) |
| NL (1) | NL300116I2 (enExample) |
| NZ (1) | NZ220894A (enExample) |
| PT (1) | PT85225B (enExample) |
| WO (1) | WO1988000205A1 (enExample) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| IL83003A (en) * | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5106748A (en) * | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US5035901A (en) * | 1987-10-09 | 1991-07-30 | University Of Kansas | Bone inducing agent from a human osteosarcoma cell line |
| US6020313A (en) * | 1987-10-09 | 2000-02-01 | University Of Kansas | Method for inducing bone formation using an extract of human osteosarcoma cell line SAOS-2 |
| US6919308B2 (en) | 1988-04-08 | 2005-07-19 | Stryker Corporation | Osteogenic devices |
| US4968590A (en) * | 1988-04-08 | 1990-11-06 | Stryker Corporation | Osteogenic proteins and polypeptides |
| US5670336A (en) * | 1988-04-08 | 1997-09-23 | Stryker Corporation | Method for recombinant production of osteogenic protein |
| US4975526A (en) * | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US5324819A (en) * | 1988-04-08 | 1994-06-28 | Stryker Corporation | Osteogenic proteins |
| US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
| US5344654A (en) * | 1988-04-08 | 1994-09-06 | Stryker Corporation | Prosthetic devices having enhanced osteogenic properties |
| WO1989010409A1 (en) * | 1988-04-08 | 1989-11-02 | Genetics Institute, Inc. | Bone and cartilage inductive compositions |
| US5258494A (en) | 1988-04-08 | 1993-11-02 | Stryker Corporation | Osteogenic proteins |
| US5108753A (en) * | 1988-04-08 | 1992-04-28 | Creative Biomolecules | Osteogenic devices |
| US5250302A (en) * | 1988-04-08 | 1993-10-05 | Stryker Corporation | Osteogenic devices |
| US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5354557A (en) * | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
| US5162114A (en) * | 1989-02-23 | 1992-11-10 | Stryker Corporation | Bone collagen matrix for xenogenic implants |
| ATE142644T1 (de) * | 1988-04-08 | 1996-09-15 | Stryker Corp | Biosynthetische osteogene proteine und sie enthaltende osteogene vorrichtungen |
| US5106626A (en) * | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
| US5284756A (en) * | 1988-10-11 | 1994-02-08 | Lynn Grinna | Heterodimeric osteogenic factor |
| US4915301A (en) * | 1988-11-15 | 1990-04-10 | International Flavors & Fragrances, Inc. | Container with sorbent member and microporous membrane for dispensing vapor from volatile liquid |
| JP3504259B2 (ja) | 1989-03-28 | 2004-03-08 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | 骨誘導組成物 |
| DK0429570T3 (da) * | 1989-03-28 | 1998-04-27 | Genetics Inst | Osteoinducerende præparater |
| JPH03151877A (ja) * | 1989-06-02 | 1991-06-28 | Chiron Corp | 骨カルシウム沈着因子 |
| CA2020729A1 (en) * | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Bone morphogenetic protein |
| WO1991002744A1 (en) * | 1989-08-21 | 1991-03-07 | Celtrix Laboratories, Inc. | Bone-specific protein |
| EP0416578B1 (en) * | 1989-09-06 | 1996-07-31 | Takeda Chemical Industries, Ltd. | Protein, DNA and use thereof |
| CA2042577A1 (en) * | 1989-10-17 | 1991-04-18 | Hermann Oppermann | Osteogenic devices |
| US5168050A (en) * | 1990-05-24 | 1992-12-01 | Genentech, Inc. | Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion |
| US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
| US5364839A (en) * | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
| DE69133338T2 (de) * | 1990-09-26 | 2004-04-15 | Genetics Institute, LLC, Cambridge | Bmp-5-derivate |
| US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
| US6090776A (en) * | 1991-03-11 | 2000-07-18 | Creative Bio Molecules, Inc. | Morphogen treatment of organ implants |
| US7056882B2 (en) | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6800603B2 (en) | 1991-03-11 | 2004-10-05 | Curis, Inc. | Morphogen-induced neural cell adhesion |
| US6399569B1 (en) | 1991-03-11 | 2002-06-04 | Curis, Inc. | Morphogen treatments for limiting proliferation of epithelial cells |
| US5656593A (en) * | 1991-03-11 | 1997-08-12 | Creative Biomolecules, Inc. | Morphogen induced periodontal tissue regeneration |
| US5674844A (en) * | 1991-03-11 | 1997-10-07 | Creative Biomolecules, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US5849686A (en) * | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
| US5972884A (en) * | 1991-03-11 | 1999-10-26 | Creative Biomolecules, Inc. | Morphogen treatment of gastrointestinal ulcers |
| CA2104678C (en) | 1991-03-11 | 2002-05-14 | Charles M. Cohen | Protein-induced morphogenesis |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| US5652337A (en) * | 1991-03-11 | 1997-07-29 | Creative Biomolecules, Inc. | OP-3-induced morphogenesis |
| US5652118A (en) * | 1991-03-11 | 1997-07-29 | Creative Biomolecules, Inc. | Nucleic acid encoding a novel morphogenic protein, OP-3 |
| US5318898A (en) * | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| AU662155B2 (en) | 1991-05-10 | 1995-08-24 | Celtrix Pharmaceuticals, Inc. | Targeted delivery of bone growth factors |
| JP3351525B2 (ja) * | 1991-06-21 | 2002-11-25 | ジェネティックス・インスティテュート・インコーポレイテッド | 骨形成性蛋白医薬処方物 |
| US6022853A (en) * | 1991-08-30 | 2000-02-08 | Creative Biomolecules, Inc. | Morphogen-enriched dietary composition |
| US5270300A (en) * | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| AU674500B2 (en) | 1991-11-04 | 1997-01-02 | Genetics Institute, Llc | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| CZ287715B6 (en) * | 1992-02-12 | 2001-01-17 | Bioph Biotech Entw Pharm Gmbh | DNA sequence, recombinant DNA molecule containing thereof, process for preparing protein from the group of TGF-beta substances, pharmaceutical preparation containing such protein, antibody or fragment thereof and its use |
| IL106278A0 (en) * | 1992-07-13 | 1993-11-15 | Sumitomo Metal Ind | Bone formation-inducing protein |
| WO1994006399A1 (en) * | 1992-09-15 | 1994-03-31 | Creative Biomolecules, Inc. | Morphogen-induced periodontal tissue regeneration |
| ATE182778T1 (de) * | 1992-09-15 | 1999-08-15 | Creative Biomolecules Inc | Durch morphogen induzierte periodontolgeweberegeneration |
| JP3681069B2 (ja) * | 1993-05-12 | 2005-08-10 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｂｍｐ−１１組成物 |
| US6333168B1 (en) * | 1993-05-20 | 2001-12-25 | The Trustees Of Columbia University In The City Of New York | Cloning, expression and uses of dorsalin-1 |
| US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| WO1995016035A2 (en) | 1993-12-07 | 1995-06-15 | Genetics Institute, Inc. | Bmp-12, bmp-13 and tendon-inducing compositions thereof |
| US5906827A (en) † | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
| CA2220555C (en) * | 1995-06-05 | 2011-07-19 | John M. Wozney | Methods and compositions for healing and repair of connective tissue attachment |
| WO1997006242A1 (en) | 1995-08-08 | 1997-02-20 | Thomas Jefferson University | Recombinant c-proteinase and processes, methods and uses thereof |
| US5807981A (en) * | 1995-12-13 | 1998-09-15 | Fibrogen Inc. | Peptides which are cleaved by C-proteinase |
| ATE493141T1 (de) | 1996-03-22 | 2011-01-15 | Stryker Corp | Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| AU5558498A (en) * | 1996-11-22 | 1998-06-22 | Akzo Nobel N.V. | Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis |
| CA2280931C (en) | 1997-02-07 | 2009-05-05 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
| US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| AU743510B2 (en) | 1997-05-05 | 2002-01-24 | Stryker Corporation | Therapies for acute renal failure |
| EP0985149A1 (en) | 1997-05-30 | 2000-03-15 | Creative Biomolecules, Inc. | Methods for evaluating tissue morphogenesis and activity |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| DE69939374D1 (de) | 1998-03-17 | 2008-10-02 | Genentech Inc | Zu vegf und bmp1 homologe polypeptide |
| US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
| US6916783B2 (en) | 1998-07-13 | 2005-07-12 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
| US6258778B1 (en) | 1998-07-13 | 2001-07-10 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
| US7572440B2 (en) | 1999-07-30 | 2009-08-11 | Stryker Corporation | Method for repairing a defect in an intervertebral disc |
| DE69933686T2 (de) | 1998-10-06 | 2007-08-23 | Rush University Medical Center, Chicago | Zusammensetzung zur verwendung in der chemonukleolyse |
| US6958149B2 (en) | 1998-10-06 | 2005-10-25 | Stryker Corporation | Repair of larynx, trachea, and other fibrocartilaginous tissues |
| JP3786533B2 (ja) | 1998-11-12 | 2006-06-14 | 善彦 西村 | ペプチド及び骨形成促進剤 |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| IL144523A0 (en) * | 1999-02-01 | 2002-05-23 | Genetics Inst | Method and compositions for healing and repair of articular cartilage |
| DE19906096A1 (de) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein mit einem Heparin-bindenden Epitop |
| JP2003510033A (ja) * | 1999-09-01 | 2003-03-18 | サブサイダリー ナンバースリー インコーポレイテッド | ヒト細胞遺伝子をダウンレギュレートすることにより、ヒト免疫不全ウイルス感染を阻止するための組成物および方法 |
| WO2001016323A2 (en) * | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| AU6865100A (en) * | 1999-09-02 | 2001-04-10 | Mitsubishi Pharma Corporation | Osteogenesis promoting agents |
| CA2386408A1 (en) | 1999-10-15 | 2001-04-26 | Genetics Institute, Inc. | Formulations of hyaluronic acid for delivery of osteogenic proteins |
| EP1354890B1 (en) | 2000-12-28 | 2007-08-08 | Shionogi & Co., Ltd. | Chordin-like polypeptides and dna thereof |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7226587B2 (en) | 2001-06-01 | 2007-06-05 | Wyeth | Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| US7160725B2 (en) | 2001-11-13 | 2007-01-09 | Curis, Inc. | Hedgehog signaling promotes the formation of three dimensional cartilage matrices |
| DE60205937T3 (de) | 2001-11-19 | 2016-01-21 | Scil Technology Gmbh | Methode zur Herstellung einer homogen beschichtete Vorrichtung mit osteoinduktiven und osteokonduktiven Eigenschaft |
| US8067557B2 (en) | 2002-03-28 | 2011-11-29 | The Trustees Of The University Of Pennsylvania | OCL-2A3 compositions and uses thereof |
| US7160994B2 (en) | 2002-03-28 | 2007-01-09 | Trustees Of The University Of Pennsylvania | Osteoclast-specific genes and proteins and uses thereof |
| PL207552B1 (pl) | 2002-09-10 | 2010-12-31 | Scil Technology Gmbh | Sposób wytwarzania urządzenia, urządzenie, kompozycja farmaceutyczna, zastosowanie urządzenia i zestaw |
| US7771755B2 (en) | 2003-09-12 | 2010-08-10 | Wyeth | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
| US8734525B2 (en) | 2003-12-31 | 2014-05-27 | Warsaw Orthopedic, Inc. | Osteoinductive demineralized cancellous bone |
| US8328876B2 (en) | 2003-12-31 | 2012-12-11 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| EP1571159A1 (en) * | 2004-03-04 | 2005-09-07 | Bayerische Julius-Maximilians-Universität Würzburg | Mutein of a bone morphogenetic protein and use thereof |
| ATE478008T1 (de) | 2004-03-10 | 2010-09-15 | Scil Technology Gmbh | Überzogene implantate, ihre herstellung und verwendung davon |
| ATE515268T1 (de) | 2004-05-25 | 2011-07-15 | Stryker Corp | Verwendung von op-1 zur behandlung von knorpeldefekten |
| US8506646B2 (en) | 2005-04-29 | 2013-08-13 | Warsaw Orthopedic, Inc. | Multi-purpose medical implant devices |
| ES2393756T3 (es) | 2005-11-01 | 2012-12-27 | Warsaw Orthopedic, Inc. | Métodos para producir composiciones de matriz ósea |
| WO2007142818A2 (en) | 2006-05-17 | 2007-12-13 | Stryker Corporation | Use of a soluble morphogenic protein complex for treating cartilage defects |
| KR20090105913A (ko) | 2006-11-02 | 2009-10-07 | 다니엘 제이 카폰 | 이동 부분을 갖는 하이브리드 면역글로불린 |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| US20100184659A1 (en) | 2006-12-21 | 2010-07-22 | Warren Jaworowicz | Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents |
| EP3207948B1 (en) | 2007-06-15 | 2020-02-26 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
| US9554920B2 (en) | 2007-06-15 | 2017-01-31 | Warsaw Orthopedic, Inc. | Bone matrix compositions having nanoscale textured surfaces |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| WO2009009688A1 (en) | 2007-07-10 | 2009-01-15 | Osteotech, Inc. | Delivery system |
| WO2009020744A1 (en) | 2007-08-07 | 2009-02-12 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations comprising gdf-5 in aqueous acidic solution |
| US8741840B2 (en) | 2008-02-13 | 2014-06-03 | Washington University | BMP-7 for use in treating neointimal hyperplasia |
| CN102026619A (zh) | 2008-04-14 | 2011-04-20 | 先进科技及再生医学有限责任公司 | 液体缓冲的gdf-5制剂 |
| WO2010093950A1 (en) | 2009-02-12 | 2010-08-19 | Osteotech, Inc. | Delivery system cartridge |
| EP2396026A2 (en) | 2009-02-12 | 2011-12-21 | Stryker Corporation | Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members |
| EP2396025A2 (en) | 2009-02-12 | 2011-12-21 | Stryker Corporation | Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease |
| CN102369212B (zh) * | 2009-03-12 | 2015-12-16 | 哈瑟投资公司 | 具有降低的bmp拮抗剂敏感性的骨形成蛋白2(bmp2)变体 |
| WO2010110974A1 (en) | 2009-03-24 | 2010-09-30 | Stryker Corporation | Methods and compositions for tissue engineering |
| US20110002897A1 (en) | 2009-06-11 | 2011-01-06 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
| SG10201403202XA (en) * | 2009-07-23 | 2014-08-28 | Agency Science Tech & Res | Pre-natal mesenchymal stem cells |
| WO2011031856A1 (en) | 2009-09-09 | 2011-03-17 | Stryker Corporation | Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint |
| EP2352750B1 (en) | 2009-09-17 | 2012-06-13 | Stryker Corporation | Buffers for controlling the ph of bone morphogenetic proteins |
| CN102822197A (zh) | 2009-12-22 | 2012-12-12 | 史赛克公司 | 具有降低的免疫原性的bmp-7变体 |
| EP3407908B1 (en) | 2016-12-30 | 2020-12-09 | Biogend Therapeutics Co., Ltd. | Recombinant polypeptides and nucleic acid molecules, compositions, and methods of making and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4563350A (en) | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4455256A (en) * | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| US4619989A (en) * | 1981-05-05 | 1986-10-28 | The Regents Of The University Of Cal. | Bone morphogenetic protein composition |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4434094A (en) * | 1983-04-12 | 1984-02-28 | Collagen Corporation | Partially purified osteogenic factor and process for preparing same from demineralized bone |
| US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
| EP0128041A3 (en) * | 1983-06-06 | 1986-12-03 | David Jeston Baylink | Polypeptides exhibiting skeletal growth factor activity |
| US4795804A (en) * | 1983-08-16 | 1989-01-03 | The Regents Of The University Of California | Bone morphogenetic agents |
| NZ210699A (en) * | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| DK518384A (da) | 1984-01-31 | 1985-07-01 | Idaho Res Found | Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse |
| US4608199A (en) * | 1984-03-20 | 1986-08-26 | Arnold Caplan | Bone protein purification process |
| GR851643B (enExample) | 1984-07-06 | 1985-11-26 | Sandoz Ag | |
| DE3588058T3 (de) | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Knorpel-induzierende Polypeptid-Faktoren aus Knochen |
| ATE78515T1 (de) | 1984-10-05 | 1992-08-15 | Genentech Inc | Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung. |
| IL83003A (en) * | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
-
1987
- 1987-06-26 IL IL8300387A patent/IL83003A/en not_active IP Right Cessation
- 1987-06-29 IE IE173987A patent/IE75881B1/en not_active IP Right Cessation
- 1987-06-30 AT AT87905023T patent/ATE141928T1/de active
- 1987-06-30 MY MYPI87000921A patent/MY102505A/en unknown
- 1987-06-30 JP JP62504617A patent/JP2713715B2/ja not_active Expired - Lifetime
- 1987-06-30 AT AT02014841T patent/ATE419349T1/de not_active IP Right Cessation
- 1987-06-30 DE DE3752393T patent/DE3752393D1/de not_active Expired - Lifetime
- 1987-06-30 DE DE3752364T patent/DE3752364T2/de not_active Expired - Lifetime
- 1987-06-30 EP EP95111771A patent/EP0688869B1/en not_active Expired - Lifetime
- 1987-06-30 WO PCT/US1987/001537 patent/WO1988000205A1/en not_active Ceased
- 1987-06-30 GR GR871028A patent/GR871028B/el unknown
- 1987-06-30 EP EP87905023A patent/EP0313578B1/en not_active Expired - Lifetime
- 1987-06-30 EP EP02014841A patent/EP1254956B1/en not_active Expired - Lifetime
- 1987-06-30 NZ NZ220894A patent/NZ220894A/xx unknown
- 1987-06-30 AT AT95111771T patent/ATE234921T1/de not_active IP Right Cessation
- 1987-06-30 MX MX007140A patent/MX170919B/es unknown
- 1987-06-30 DE DE3751887T patent/DE3751887T2/de not_active Expired - Lifetime
- 1987-06-30 AU AU77835/87A patent/AU613314B2/en not_active Expired
- 1987-06-30 ES ES8701909A patent/ES2007625A6/es not_active Expired
- 1987-06-30 CA CA000540928A patent/CA1341212C/en not_active Expired - Fee Related
- 1987-06-30 DE DE2003199007 patent/DE10399007I2/de active Active
- 1987-07-01 PT PT85225A patent/PT85225B/pt unknown
-
1988
- 1988-02-29 DK DK106288A patent/DK172275B1/da not_active IP Right Cessation
-
1993
- 1993-06-01 JP JP5130389A patent/JP2729222B2/ja not_active Expired - Lifetime
-
1997
- 1997-05-09 DK DK199700534A patent/DK172503B1/da not_active IP Right Cessation
- 1997-06-27 JP JP09171615A patent/JP3093682B2/ja not_active Expired - Lifetime
-
2003
- 2003-01-29 LU LU91005C patent/LU91005I2/fr unknown
- 2003-02-24 NL NL300116C patent/NL300116I2/nl unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4563350A (en) | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
Non-Patent Citations (1)
| Title |
|---|
| Ｐｒｏｃ．Ｎａｔｕｌ．Ａｃａｄ．Ｓｃｉ．ＵＳＡ，８１ （１９８４），Ｐ．３７１−３７５ |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2713715B2 (ja) | 新規骨誘導組成物 | |
| US5618924A (en) | BMP-2 products | |
| US4877864A (en) | Osteoinductive factors | |
| US5459047A (en) | BMP-6 proteins | |
| US5187076A (en) | DNA sequences encoding BMP-6 proteins | |
| US7300772B2 (en) | BMP products | |
| US6177406B1 (en) | BMP-3 products | |
| CA2030518C (en) | Osteoinductive compositions | |
| AU645244B2 (en) | Bone and cartilage inductive compositions | |
| US5631142A (en) | Compositions comprising bone morphogenetic protein-2 (BMP-2) | |
| US5141905A (en) | Dna sequences encoding bmp-7 proteins | |
| US5635373A (en) | Bone morphogenic protein-5(BMP-5) and DNA encoding same | |
| EP0550625B1 (en) | Bmp-5 derivatives | |
| KR970005583B1 (ko) | 골 유도(oseteoinductive) 조성물 | |
| US20070026437A1 (en) | Novel BMP products | |
| JP2004073208A (ja) | 骨誘導組成物 | |
| IE83704B1 (en) | Novel osteoinductive factors | |
| NO310029B1 (no) | Fremgangsmåte for fremstilling av huBMP-2 klasse I (BMP-2) og II (BMP-4) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071031 Year of fee payment: 10 |